

bluebird bio, Inc.  
Form 8-K  
June 16, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 14, 2014**

**bluebird bio, Inc.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State or other jurisdiction**

**of incorporation)**

**001-35966**  
**(Commission**

**File Number)**

**13-3680878**  
**(I.R.S. Employer**

**Identification No.)**

**150 Second Street**

**Cambridge, MA**

**(Address of principal executive offices)**

**02141**

**(Zip Code)**

**Registrant's telephone number, including area code (339) 499-9300**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure**

On June 16, 2014, bluebird bio, Inc. ( bluebird ) conducted an investor webcast summarizing clinical data from its HGB-205 clinical trial that was presented at an oral presentation at the 19<sup>th</sup> European Hematology Association Congress in Milan, Italy on June 14, 2014. A copy of the presentation is being furnished as Exhibit 99.2 to this Report on Form 8-K.

The information in Item 7.01 of this Report on Form 8-K and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing

**Item 8.01 Other Events**

On June 14, 2014, issued a press release announcing clinical data from its HGB-205 clinical trial at an oral presentation at the 19<sup>th</sup> European Hematology Association Congress in Milan, Italy on June 14, 2014. The full text of bluebird s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit

No.	Description
99.1	Press release issued by bluebird bio, Inc. on June 14, 2014.
99.2	Investor presentation provided by bluebird bio, Inc. on June 16, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 16, 2014

**bluebird bio, Inc.**

By: /s/ Jason F. Cole

Jason Cole

*Senior Vice President, General Counsel*

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press release issued by bluebird bio, Inc. on June 14, 2014.
99.2	Investor presentation provided by bluebird bio, Inc. on June 16, 2014.